ABOS
Acumen Pharmaceuticals, Inc. [ABOS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ABOS Stock Summary
Top 10 Correlated ETFs
ABOS
Top 10 Correlated Stocks
ABOS
In the News
ABOS Financial details
Company Rating
Neutral
Market Cap
224.7M
Income
-50.54M
Revenue
0
Book val./share
4.61
Cash/share
4.21
Dividend
-
Dividend %
-
Employees
51
Optionable
No
Shortable
Yes
Earnings
06 May 2024
P/E
-4.92
Forward P/E
-
PEG
-16.4
P/S
-
P/B
0.84
P/C
0.76
P/FCF
-5.48
Quick Ratio
35.33
Current Ratio
35.85
Debt / Equity
0.12
LT Debt / Equity
0.11
-
-
EPS (TTM)
-1.03
EPS next Y
-
EPS next Q
-
EPS this Y
8%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
40.11%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
16.67%
-
-
-
-
SMA20
-
SMA50
33.33%
SMA100
100%
Inst Own
69.1%
Inst Trans
1.08%
ROA
-17%
ROE
-23%
ROC
-0.2%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.81-11.31
52W High
-70.95%
52W Low
+219.5%
RSI
34
Rel Volume
1.61
Avg Volume
361.14K
Volume
580.55K
Perf Week
-13.88%
Perf Month
-26.89%
Perf Quarter
-0.78%
Perf Half Y
-14.8%
-
-
-
-
Beta
0.082
-
-
Volatility
0.2%, 0.29%
Prev Close
-7.93%
Price
3.195
Change
-8.71%
ABOS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.04 | 0.04 | 0 | 0 | 0 | |
| Net income per share | -0.2 | -0.18 | -4.49 | -1 | -1.08 | |
| Operating cash flow per share | -0.17 | -0.19 | -0.44 | -0.87 | -0.89 | |
| Free cash flow per share | -0.17 | -0.19 | -0.44 | -0.87 | -0.89 | |
| Cash per share | 0.16 | 1.09 | 4.8 | 4.37 | 5.01 | |
| Book value per share | -0.28 | -0.46 | 5.56 | 4.65 | 5.49 | |
| Tangible book value per share | -0.28 | -0.46 | 5.56 | 4.65 | 5.49 | |
| Share holders equity per share | -0.28 | -0.46 | 5.56 | 4.65 | 5.49 | |
| Interest debt per share | 0 | 0 | 0 | -0.06 | 0.62 | |
| Market cap | 807.05M | 807.05M | 273.6M | 219.25M | 186.66M | |
| Enterprise value | 800.5M | 763.27M | 151.44M | 89.25M | 150.82M | |
| P/E ratio | -102.65 | -110.19 | -1.51 | -5.42 | -3.56 | |
| Price to sales ratio | 475.58 | 562.01 | 0 | 0 | 0 | |
| POCF ratio | -118.37 | -108.33 | -15.23 | -6.24 | -4.33 | |
| PFCF ratio | -118.37 | -108.33 | -15.2 | -6.21 | -4.33 | |
| P/B Ratio | -70.67 | -43.41 | 1.22 | 1.16 | 0.7 | |
| PTB ratio | -70.67 | -43.41 | 1.22 | 1.16 | 0.7 | |
| EV to sales | 471.71 | 531.53 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -104.53 | -89.82 | 2.46 | -1.98 | -2.47 | |
| EV to operating cash flow | -117.41 | -102.45 | -8.43 | -2.54 | -3.5 | |
| EV to free cash flow | -117.41 | -102.45 | -8.41 | -2.53 | -3.5 | |
| Earnings yield | -0.01 | -0.01 | -0.66 | -0.18 | -0.28 | |
| Free cash flow yield | -0.01 | -0.01 | -0.07 | -0.16 | -0.23 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0.12 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0.1 | |
| Net debt to EBITDA | 0.86 | 5.15 | -1.98 | 2.88 | 0.59 | |
| Current ratio | 5.35 | 6.98 | 38.6 | 23.08 | 19.01 | |
| Interest coverage | 0 | 0 | 0 | 19 | 105.23 | |
| Income quality | 0.86 | 1.02 | 0.18 | 0.82 | 0.82 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.55 | 0.94 | 0 | 0 | 0 | |
| Research and developement to revenue | 5.05 | 5.57 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | -10 | -0.95 | -0.11 | |
| Stock based compensation to revenue | 0.1 | 0.11 | 0 | 0 | 0 | |
| Graham number | 1.12 | 1.38 | 23.71 | 10.21 | 11.54 | |
| ROIC | 0.68 | 0.43 | 0.49 | -0.23 | -0.21 | |
| Return on tangible assets | -1.07 | -0.16 | -0.79 | -0.21 | -0.17 | |
| Graham Net | -0.3 | -0.48 | 4.67 | 4.18 | 4.13 | |
| Working capital | 5.84M | 38.06M | 193.51M | 172.52M | 233.64M | |
| Tangible asset value | -11.42M | -18.59M | 225.18M | 188.78M | 266.97M | |
| Net current asset value | -11.56M | -18.59M | 193.51M | 172.52M | 203.46M | |
| Invested capital | 0 | 0 | 0 | 0 | 0.12 | |
| Average receivables | 0 | 69.5K | 54.46K | -141 | 112.4K | |
| Average payables | 0 | 377K | 809.5K | 1.36M | 1.51M | |
| Average inventory | 0 | 70K | 45.54K | 141 | 99.5 | |
| Days sales outstanding | 6.45 | 27.71 | 0 | 0 | 0 | |
| Days payables outstanding | 9.49K | 24.24K | 99.28K | 3.54K | 2.74K | |
| Days of inventory on hand | 2.09K | 4.15K | 7.57 | 0.43 | 0 | |
| Receivables turnover | 56.57 | 13.17 | 0 | 0 | 0 | |
| Payables turnover | 0.04 | 0.02 | 0 | 0.1 | 0.13 | |
| Inventory turnover | 0.18 | 0.09 | 48.19 | 849.25 | 0 | |
| ROE | 0.69 | 0.39 | -0.81 | -0.21 | -0.2 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.34 | -0.23 | -0.28 | -0.24 | -0.28 | |
| Operating cash flow per share | -0.27 | -0.25 | -0.28 | -0.24 | -0.14 | |
| Free cash flow per share | -0.28 | -0.25 | -0.28 | -0.24 | -0.14 | |
| Cash per share | 4.35 | 3.42 | 3.53 | 3.97 | 4.21 | |
| Book value per share | 4.62 | 4.37 | 4.12 | 5.17 | 4.61 | |
| Tangible book value per share | 4.62 | 4.37 | 4.12 | 5.17 | 4.61 | |
| Share holders equity per share | 4.62 | 4.37 | 4.12 | 5.17 | 4.61 | |
| Interest debt per share | -0.01 | -0.04 | 0 | 0 | 0.54 | |
| Market cap | 220.66M | 166.56M | 197.33M | 225.05M | 222.38M | |
| Enterprise value | 90.66M | 88.63M | 120.11M | 130.14M | 186.54M | |
| P/E ratio | -3.98 | -4.39 | -4.25 | -4.34 | -3.37 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -19.7 | -16.37 | -16.91 | -17.44 | -26.75 | |
| PFCF ratio | -19.63 | -16.37 | -16.91 | -17.43 | -26.7 | |
| P/B Ratio | 1.17 | 0.93 | 1.17 | 0.8 | 0.83 | |
| PTB ratio | 1.17 | 0.93 | 1.17 | 0.8 | 0.83 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -6.39 | -6.77 | -8.95 | -8.11 | -10.11 | |
| EV to operating cash flow | -8.09 | -8.71 | -10.29 | -10.08 | -22.44 | |
| EV to free cash flow | -8.07 | -8.71 | -10.29 | -10.08 | -22.4 | |
| Earnings yield | -0.06 | -0.06 | -0.06 | -0.06 | -0.07 | |
| Free cash flow yield | -0.05 | -0.06 | -0.06 | -0.06 | -0.04 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0.12 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0.1 | |
| Net debt to EBITDA | 9.16 | 5.96 | 5.75 | 5.92 | 1.94 | |
| Current ratio | 23.08 | 16.41 | 17.53 | 35.85 | 19.01 | |
| Interest coverage | 29.75 | 7.19 | 0 | 0 | -31.82 | |
| Income quality | 0.87 | 0.9 | 1.01 | 1 | 0.5 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.71 | 0 | 0 | -0.18 | -0.36 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 5.94 | 4.76 | 5.12 | 5.27 | 5.44 | |
| ROIC | -0.08 | -0.06 | -0.07 | -0.06 | -0.06 | |
| Return on tangible assets | -0.07 | -0.05 | -0.07 | -0.05 | -0.05 | |
| Graham Net | 4.18 | 3.21 | 3.37 | 3.86 | 3.46 | |
| Working capital | 172.52M | 135.25M | 141.01M | 212.5M | 233.64M | |
| Tangible asset value | 188.78M | 179.09M | 168.87M | 280.27M | 266.97M | |
| Net current asset value | 172.52M | 135.25M | 141.01M | 212.5M | 203.46M | |
| Invested capital | 0 | 0 | 0 | 0 | 0.12 | |
| Average receivables | 1.59M | 652.4K | 1.36M | 1.36M | 112.5K | |
| Average payables | 1.86M | 1.2M | 1.39M | 1.69M | 1.37M | |
| Average inventory | 200 | 795 | 2.03K | 1.34K | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 3.01K | 1.32K | 3.44K | 3.06K | 3.18K | |
| Days of inventory on hand | 0.37 | 2.41 | 4.55 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.03 | 0.07 | 0.03 | 0.03 | 0.03 | |
| Inventory turnover | 246.23 | 37.38 | 19.79 | 0 | 0 | |
| ROE | -0.07 | -0.05 | -0.07 | -0.05 | -0.06 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
ABOS Frequently Asked Questions
What is Acumen Pharmaceuticals, Inc. stock symbol ?
Acumen Pharmaceuticals, Inc. is a US stock , located in Charlottesville of Va and trading under the symbol ABOS
What is Acumen Pharmaceuticals, Inc. stock quote today ?
Acumen Pharmaceuticals, Inc. stock price is $3.195 today.
Is Acumen Pharmaceuticals, Inc. stock public?
Yes, Acumen Pharmaceuticals, Inc. is a publicly traded company.
Company Profile
- Volume Average 361.14K
- Market Capitalization 224.7M
- Employee 51
- CEO Mr. Daniel J. O'Connell M.B.A.
- Headquarters Charlottesville,VA,US
- IPO Date 2021-07-01
-
Website
https://acumenpharm.com 
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
